The statement of the Polish Society of Allergology regarding necessary changes in therapeutic program of severe IgE-mediated allergic asthma with omalizumab

Pneumonol Alergol Pol. 2015;83(4):335-8. doi: 10.5603/PiAP.2015.0053.

Authors

Zbigniew Bartuzi, Anna Bodzenta-Łukaszyk, Piotr Kuna¹, Izabela Kupryś-Lipińska, Ewa Niżankowska-Mogilnicka, Bolesław Samoliński

Affiliation

¹ Department of Internal Medicine, Asthma and Allergy, University Hospital N. Barlicki, Łódź, Poland. [email protected].

PMID: 26166795
DOI: 10.5603/PiAP.2015.0053

No abstract available

Publication types

Consensus Development Conference

MeSH terms

Anti-Asthmatic Agents / therapeutic use*
Asthma / drug therapy*
Asthma / immunology*
Guidelines as Topic
Humans
Immunoglobulin E / immunology
Omalizumab / therapeutic use*
Poland

Substances

Anti-Asthmatic Agents
Omalizumab
Immunoglobulin E